Nitrite is a promising therapeutic agent for the treatment of cardiovascular disease. 8 Nitrite is a stable oxidative metabolic product of NO that is readily reduced back to NO in hypoxic and Objective: No evidence exists as to whether increasing NO bioavailability via nitrite therapy attenuates heart failure severity after pressure-overload-induced hypertrophy.
L eft ventricular (LV) hypertrophy is a maladaptive response to chronic pressure overload and an important risk factor for atrial fibrillation, diastolic heart failure, systolic heart failure, and sudden death in patients. 1 The integrity of the cardiovascular system is dependent on the continuous generation of nitric oxide (NO). As such, reduction in the bioavailability of NO is central to the development of cardiovascular disorders, including heart failure. 2 For instance, patients with class III heart failure have blunted endothelium-dependent flow-mediated dilatation in response to acetylcholine infusion indicative of diminished NO release. NO bioavailability is affected by the activity of the 3 NO synthases (NOS) and the presence of reactive oxygen species. In heart failure, the activity of endothelial NOS (eNOS) is reduced, and there is an increase in reactive oxygen species levels because of decreased antioxidant defenses. 3 Further evidence that eNOS/NO provides protection against heart failure comes from animal studies in which genetic overexpression of eNOS protects against, 4 whereas the genetic deficiency of eNOS enhances the development of heart failure. 5 Pharmacological approaches to upregulate eNOS function have been shown to decrease the severity of heart failure. 6 Therefore, therapeutic agents that enhance NO bioavailability, improve NO signaling, or provide a more favorable shift in redox balance may improve the outcome of heart failure. acidic environments. 9 Previously it has been demonstrated that administration of nitrite attenuates the severity of ischemia/reperfusion injury in many organs. 10, 11 We have shown that nitrite reduces myocardial ischemia/reperfusion injury. 10, 12 However, no evidence exists as to whether increasing NO bioavailability through nitrite therapy attenuates chronic heart failure. The purpose of the current study was to investigate the effects of sustained sodium nitrite therapy after transverse aortic constriction (TAC).
Methods

Experimental Animals
Male C57BL/6J mice and CS-eNOS transgenic mice at 10 to 12 weeks (Jackson Laboratories, Bar Harbor, ME) were used. All animals were housed in a temperature-controlled animal facility with a 12-hour light/dark cycle, with water and rodent chow provided ad libitum. 
Serum Samples From Patients With Heart Failure:
The Atlanta Cardiomyopathy Consortium (TACC) Study Serum samples were obtained from patients enrolled in the TACC study. This prospective cohort study enrolls patients from the Emory University-affiliated teaching hospitals. All patients undergo detailed medical history surveys, ECG, standardized questionnaires, and blood and urine sample collection at baseline. All patients provide written informed consent before enrollment. The Emory University Institutional Review Board has approved this study.
TAC Protocol
To establish myocardial pressure overload and heart failure, TAC surgery was performed as described previously. 13,13a The complete experimental protocol for these studies is depicted in Figure 2A .
Echocardiography and Hemodynamic Assessment
One week before TAC procedure, baseline transthoracic echocardiogram was performed using 30-MHz probe on a Vevo 2100 (Visualsonics) under anesthesia with isoflurane (0.25%-0.50%) supplemented with 100% O 2 . After TAC procedure, echocardiography was also performed in the same manner for ≤9 weeks at fixed intervals, and pulsed-wave Doppler mode was used to measure hemodynamic assessment of aortic peak flow velocity at 1 week.
Western Blot Analysis
Western blot analysis was performed as described previously.
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Myocardial Measurement of NO Metabolites
Nitrite (NO 2 -) nitroso products (RXNO) analysis of cardiac tissue and blood plasma were performed as previously described.
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Measurements of Serum and Myocardial Brain Natriuretic Peptide
Serum levels of brain natriuretic peptide (BNP; EIA kit; Phoenix Pharmaceuticals, Inc) were determined by ELISA at 6 weeks after TAC. Myocardial RNA levels of BNP were determined using polymerase chain reaction methods as described previously. 16 
cGMP Radioimmunoassay
The cGMP radioimmunoassay was modified from the study by Steiner et al. 17 Briefly, cGMP standards (Sigma) and samples were acetylated by adding 8 μL of 5 NKOH and 2 μL of acetic anhydride in a volume of 200 μL and incubated at room temperature for 30 minutes. Then tubes were placed on ice to stop the reaction. All determinations were performed in duplicate. Each tube contained 50-μL acetylated standards or samples, 50-μL iodinated cGMP (14 000-16 000 cpm), and 50-μL cGMP antibody (Sigma). The reaction mixture was incubated overnight at 4°C. Then cGMP-antibody complex were precipitated by 12% polyethylene glycol 8000.
Histology and Immunochemistry
Hearts were collected at the specific time points and fixed in 10% buffered formalin, embedded in paraffin stained with Masson trichome and Picrosirius Red to detect fibrosis. Immunohistochemistry was performed to visualize vascular density with a commercially available kit (Blood Vessel staining kit; Millipore). In additional studies, mice were subjected to TAC for 6 weeks at which time lungs were harvested, fixed in 10% buffered formalin, embedded in paraffin, sectioned and stained with hematoxylin and eosin stain to determine the extent of pulmonary inflammation and edema.
Statistical Analysis
All data are expressed as mean±SEM. Student t test or a 1-way ANOVA with Tukey or Dunnett post hoc analysis was performed using Prism 5 (GraphPad Software). Values >2 SDs outside the mean were considered as outliers. A value of P<0.05 was considered as statistically significant.
Results
Serum Levels of NO Metabolites and cGMP Are Decreased in Heart Failure
We evaluated circulating levels of NO intermediates in patients with heart failure (n=127) when compared with age-matched control subjects (n=93), and these data are depicted in Figure 1A and 1C. We failed to observe any differences in serum nitrite levels (μmol/L) in heart failure when compared with age-matched controls ( Figure 1A ). However, total serum RXNO (nmol/L) were significantly (P<0.001) reduced in patients with heart failure ( Figure 1B ). Serum cGMP levels (pmol/mL) were also reduced in the patients with heart failure (P<0.01 versus control) when compared with the controls ( Figure 1C ).
Effects of Nitrite Therapy on NO Metabolites and cGMP Levels in Mice
To investigate the role of nitrite therapy in pressure-overloadinduced hypertrophy and heart failure, we performed TAC surgery in mice (Figure 2 ). Oral nitrite therapy (50 mg/L) was initiated postoperative day 1 after TAC surgery and was provided in drinking water continuously for 9 weeks. This oral nitrite resulted in the delivery of ≈9 to 12 mg/kg per day to the mice ( Figure I in the online-only Data Supplement). To evaluate the effects of nitrite therapy on NO bioavailability and signaling, we examined serum and cardiac nitrite, RXNO, and cGMP levels in mice subjected to TAC (Figure 2 ). Similar to our clinical data TAC-induced heart failure resulted in decreased levels of serum nitrite (P<0.05 versus sham), serum RXNO, serum cGMP, and cardiac RXNO. Nitrite therapy after TAC restores serum RXNO (P<0.001), serum cGMP 
Adverse Cardiac Remodeling and Pulmonary Edema Are Attenuated With Preserved LV Function
Representative photomicrographs of sham mouse hearts and TAC+vehicle or TAC+nitrite are shown in Figure II in the online-only Data Supplement. We evaluated circulating BNP levels (ng/mL), heart/tibia length (mg/cm), and lung/tibia weights (mg/cm), and these data are presented in Figures 3A to 3C. Cardiac structure and function were evaluated using echocardiography ( Figure 3D -3F). Circulating BNP levels serve as a reliable biomarker of heart failure severity in both humans and animal models. BNP levels increased significantly in TAC-vehicle mice at 6 weeks when compared with sham mice, and nitrite treatment significantly (P<0.05) inhibited BNP levels when compared with vehicle after TAC ( Figure 3A ). Myocardial tissue BNP mRNA expression was also determined using quantitative polymerase chain reaction methods ( Figure II in the online-only Data Supplement). Cardiac enlargement was confirmed by the heart weight/tibia length ratios, demonstrating that the hearts of vehicle mice were significantly increased when compared with that of sham mice at 6 and 9 weeks after TAC (P<0.001). Nitrite-treated mice exhibited significantly increased heart weight/tibia length when compared with sham mice at 9 weeks after TAC (P<0.01), but these increases were less when compared with vehicle mice ( Figure 3B ). Nitrite-treated mice displayed significantly less pulmonary edema when compared with vehicle mice at 9 weeks ( Figure 3C ).
Nitrite treatment significantly prevented cardiac dilatation (LV end-diastolic diameter at 9 weeks; 4.8±0.2 mm in vehicle versus 3.5±0.1 mm in nitrite and LV end-systolic diameter at 9 weeks; 4.1±0.3 mm in vehicle versus 2.3±0.2 mm in nitrite; Figure 3D and 3E). Nitrite also attenuated LV dysfunction ( Figure 3F ) as assessed by LV ejection fraction (33.3±4.3% in vehicle versus 66.1±4.1% in nitrite; P<0.001 at 9 weeks). Despite robust cardiac protection, we failed to observe any changes in survival with nitrite after TAC ( Figure III in the online-only Data Supplement). Survival of mice receiving vehicle was 59% and in mice receiving nitrite was 65% (P=NS).
We also investigated the effects of oral nitrite started at 3 weeks after TAC (ie, delayed nitrite therapy) and evaluated cardiac function at baseline, 1, 3, 6, and 9 weeks after TAC ( Figure 4 ). Nitrite treatment significantly prevented cardiac dilatation (LV end-diastolic diameter at 9 weeks; 4.38±0.1 mm in vehicle versus 3.4±0.1 mm in nitrite and LV end-systolic diameter at 9 weeks; 3.5±0.2 mm in vehicle versus 2.2±0.1 mm in nitrite; Figure 4A and 4B). Nitrite also attenuated LV dysfunction ( Figure 4C ) as assessed by LV ejection fraction (38.8±3.1% in vehicle versus 63.9±3.0% in nitrite; P<0.001 at 9 weeks).
Hemodynamic Assessment of Aorta After TAC (Peak Velocity)
We measured aortic peak velocity after aortic banding in both the groups at 1 week after TAC. Peak velocity was elevated significantly in both the groups after TAC when compared with sham mice without TAC at each time (data not shown). There was no significant difference between the groups (3055.4±42 mm/s in vehicle versus 3265.3±67.1 mm/s in nitrite) at 1 week thus indicating a similar severity of TAC in both study groups. 
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Overexpression of eNOS Attenuates Cardiac Dysfunction After TAC
Cardiac-restricted overexpression of eNOS significantly increases nitrite and other NO metabolites in the heart and circulation. 18 We examined whether overexpression of eNOS within the cardiac myocyte attenuates cardiac hypertrophy and dysfunction after TAC using CS-eNOS transgenic mice (Figure V in the online-only Data Supplement). There was no difference in the mortality between both groups (data not shown). CS-eNOS transgenic mice exhibited significantly less cardiac enlargement and pulmonary edema, as assessed by the ratio of heart and lung weights to tibia length (mg/cm) when compared with wild-type controls ( Figure VA 
Nitrite Attenuates Cardiac Fibrosis and Augments Vascular Density
Masson Trichome and Picrosirius Red staining at 6 weeks after TAC ( Figure 5A-5C ) revealed extensive areas of intermuscular and perivascular fibrosis in hearts of vehicle TAC mice (P<0.05 versus sham) with significantly less fibrosis after nitrite therapy ( Figure 5B and 5C ). We also evaluated myocardial vascular density at 6 weeks after TAC surgery in vehicle and nitrite-treated hearts ( Figure 5A and 5D ). These data indicate significant vascular dropout after TAC that is partially restored with nitrite treatment (P<0.05 versus vehicle).
Nitrite Augments Akt-eNOS Signaling Acutely After TAC
The serine/threonine kinase Akt regulates cardiac growth, angiogenesis, and survival. 19 We investigated whether nitrite altered Akt phosphorylation in the heart after TAC ( Figure 6A-6C ).
Representative Western blots for Akt phosphorylation status in the heart at 1 and 6 weeks after TAC are shown in Figure 6A . Total Akt levels in the both vehicle and nitrite-treated mice significantly increased at 1 week after TAC and in nitrite-treated mice at 6 weeks. Nitrite treatment significantly increased the phosphorylated Akt at threonine residue 308 (Akt-P
Thr308
; P<0.001) and serine residue 473 (Akt-P Ser473 ; P<0.001) when compared with vehicle mice at 1 week after TAC ( Figure 6B and 6C) . Interestingly, both Akt-P Thr308 (P<0.05) and Akt-P Ser473 (P<0.001) were significantly attenuated by nitrite treatment when compared with vehicle mice at 6 weeks after TAC ( Figure 6B and 6C) .
Upregulation of Akt results in eNOS activation to generate NO that modulates vascular angiogenesis and to promote vascular and myocardial cytoprotection. 20 To investigate the involvement of eNOS function after TAC, the expression and the phosphorylation status of eNOS at serine residue 1177 (eNOS-P Ser1177 ) were assessed by Western blot analysis ( Figure 6D-6F ). There were no differences in total eNOS expression in the heart among all groups ( Figure 6E ). However, the eNOS activation site (eNOS-P Ser1177 ) exhibited significantly greater phosphorylation ( Figure 6F ) in the nitrite group when compared with either sham (P<0.01) or vehicle mice (P<0.01) at 1 week. Similar to the activation of Akt, the increase in eNOS phoshorylation at Ser 1177 was transient and not observed at 6 weeks after TAC.
Nitrite Augments GSK3β Signaling Inhibition in Acute Phase After TAC
Phosphorylation of protein kinase B/Akt has been linked with the inhibition of glycogen synthase kinase-3 beta (GSK3β) through phosphorylation at serine residue 9. 21 Furthermore, we investigated whether nitrite treatment altered GSK3β phosphorylation in the heart after TAC (Figure 7) . Representative Western blots for GSK3β phosphorylation status in the heart at 1 and 6 weeks after TAC are shown in Figure 7A . Total GSK3β levels in the both vehicle and nitrite-treated mice remained the same at 1 and 6 weeks after TAC ( Figure 7B ). Nitrite treatment significantly increased the expression of phosphorylated-GSK3β at ser9 when compared with vehicle mice (P<0.05) at 1 week ( Figure 7C ). There were no differences in GSK3β phosphorylation between the nitrite and vehicle groups at 6 weeks after TAC as shown in Figure 7C .
Nitrite Augments ERK1/2 Signaling After TAC
Extracellular signal-regulated kinases (ERK1/2) are a known regulator of cardiac hypertrophy. 22 We investigated whether nitrite treatment altered ERK phosphorylation in the heart after TAC (Figure 8A-8C) . Representative Western blots for ERK phosphorylation status in the heart at 1 and 6 weeks after TAC are shown in Figure 8A . Total ERK levels ( Figure 8B ) in the both vehicle and nitrite-treated mice significantly increased at 1 and 6 weeks after TAC. Nitrite treatment significantly increased the expression of phosphorylated-ERK1/2 when compared with vehicle mice (P<0.001) at 1 and 6 weeks (P<0.05) after TAC ( Figure 8C ).
Nitrite Attenuates p38 Signaling After TAC
Previous studies have shown that activation of p38 leads to cardiac dysfunction by reducing LV function and increasing cardiac fibrosis. 23, 24 We investigated the phosphorylation status of p38 at 1 and 6 weeks after TAC (Figure 8D-8F) .
Representative Western blots for P38 phosphorylation status in the heart at 1 and 6 weeks after TAC are shown in Figure 8D . We found that nitrite treatment significantly attenuated p38 activation at 6 weeks when compared with the vehicle group, but failed to show any change at 1 week after TAC ( Figure 8F ).
Nitrite Attenuates Lung Inflammation and Edema
We also investigated the effect of oral nitrite on lung tissue after TAC in both the control and the nitrite-treated mice at 6 weeks. We found that in the nitrite treatment group, there is less inflammation and edema, as well less thicker alveolar walls, when compared with the vehicle group at 6 weeks. Representative pictures were taken at ×5 and ×20 magnification for both the groups ( Figure IV in the online-only Data Supplement).
Discussion
Alterations in NO bioavailability play a prominent role in the development of heart failure. 7, 25 Studies have shown that enhancing NO levels through genetic manipulation leads to improved survival, 4 decreased remodeling 26 and improved cardiac function after ischemia-induced heart failure. Furthermore, eNOS-derived NO exerts antihypertrophic effects in the heart as evidenced by the findings that eNOS-deficient animals exhibit hypertension and cardiac hypertrophy. 27, 28 Moreover, cardiac-specific overexpression of eNOS attenuates isoproterenol-induced cardiac hypertrophy. The current study provides several lines of evidence to support these previous findings. Our study clearly demonstrates reductions in circulating levels of nitrosothiols and cGMP in patients with heart failure. We also demonstrate significant reductions in circulating and cardiac NO metabolites and cGMP in the setting of TAC-induced heart failure in mice. We also demonstrate that chronic oral nitrite therapy provides protection against the adverse remodeling and LV dysfunction associated with heart failure. Our findings suggest that increasing NO bioavailability in the myocardium protects against the development of pressure-induced heart failure.
The role of NO in the pathophysiology and treatment of chronic heart failure is not without controversy. Studies report that NO contributes to detrimental cardiac function in heart failure. 30 In addition, Takimoto et al 31 suggested that pressure overload results in eNOS-uncoupling resulting in increased myocardial oxidant production and exacerbated cardiac dysfunction. In sharp contrast to these findings, we found that the genetic overexpression of eNOS in the heart provided protection against the adverse remodeling and impaired LV function associated with TAC and not exacerbated cardiac pathology. In addition, the effect of NO on the mitochondria is recognized as one of its cardioprotective actions because this leads to a decrease of myocardial injury by extending the zone of adequate tissue cellular oxygenation away from vessels. 32 Furthermore, physicians have been successfully using drugs that are able to activate eNOS (ie, ACE-I [angiotensin-converting enzyme-1] and ARB [angiotensin receptor blocker]) or increase NO bioavailability (ie, ISDN-hydralazine-Bidil) in the treatment of heart failure. 33 Likewise, increasing the NO second messenger, cGMP, after sildenafil treatment has been shown to improve exercise capacity in patients with heart failure. 34 Finally, statins that augment eNOS-NO signaling have been shown to prolong survival in a murine model of heart failure. 35 Therefore, evidence is accumulating that under the appropriate conditions, NO in general, and eNOS-derived NO in particular, impart cardioprotective effects in the failing heart. 36 In an effort to provide insights into the mechanisms regulating the progression of heart failure, Haq et al 40 investigated the activity of several signaling cascades in heart samples taken from patients with compensated cardiac hypertrophy and advanced heart failure. Although they found a clear prohypertrophic activity profile in both patient populations, the signaling cascades activated in both were distinct. The results of the current study suggest that nitrite therapy prevents the development of heart failure in response to TAC. We evaluated the effects of nitrite therapy on multiple signal transduction pathways activated in response to heart failure to further elucidate the mechanisms by which nitrite protects the failing heart. We focused our analysis on 2 time points, representing an acute onset of hypertrophy (1 week) and heart failure (6 weeks).
The serine/threonine protein kinase Akt regulates cardiac growth, contractile function, and cell death and also is an important factor for VEGF-mediated angiogenesis. 37 Our data suggest that nitrite therapy rapidly induces Akt activation, resulting in eNOS phosphorylation and inhibition of GSK3β at 1 week after the induction of aortic constriction. At 6 weeks of TAC, Akt phosphorylation remained elevated in the vehicle group but returned to baseline levels in the nitrite group. Previous studies suggest that short-term activation of Akt in cardiac muscle protects from contractile dysfunction in the failing heart, 38 whereas long-term activation switches the heart from an adaptive, compensated state with preserved function to a pathological state with cardiac dysfunction. 39 Our findings support the notion that Akt can exerts a dual role in the development of heart failure after TAC. The activation of Akt in the failing heart is due to a number of stress-related stimuli. 40 As such, the persistent activation of Akt observed in the vehicletreated heart at 6 weeks after TAC could be indicative of still present stimuli. Likewise, the decrease in Akt activation observed in the nitrite-treated hearts could be because of a reduction in these stimuli at the 6-week time point. Akt signaling is well known to occur in cardiac hypertrophy and perhaps some of the mixed results could reflect a combination of survival signaling and cell growth stimulation. Further studies are required to determine the exact mechanism by which nitrite therapy modulates Akt activation during the development of heart failure. GSK3β regulates a wide variety of cellular functions and serves as a master regulator of cell growth and death in cardiac myocytes in response to hypertrophic stimuli. 41 The activity of GSK3β is negatively regulated by Akt and inhibiting GSK3β is critical to the antiapoptotic effects of Akt and to the hypertrophic response of cardiomyocytes. 40, 42 Our findings suggests that nitrite therapy prevents the transition from compensated to decompensated heart failure via the inhibition GSK3β.
We also demonstrate that nitrite therapy increases the activation of MAPK/ERK kinase (MEK1)-ERK1/2 signaling and attenuates p38 activation. Specifically, we found that nitrite therapy rapidly induces ERK1/2 activation at 1 week after the induction of aortic constriction. At 6 weeks of TAC, ERK1/2 phosphorylation levels remained higher in the nitritetreated group when compared with the vehicle-treated group. However, the level of phosphorylation in the nitrite-treated group was similar to those found in sham animals. In regards to p38 activation, we found that nitrite therapy reduced the level of p38 phosphorylation at 6 weeks of TAC. It has been demonstrated that activation of MEK1-ERK1/2 signaling regulates hypertrophic response in vivo 22 and promotes compensated cardiac hypertrophy and preservation of cardiac function. 43 In addition to the reported hypertrophic effects of ERK1/2 signaling, the enhanced activation of this pathway has been shown to provide cardioprotection via robust antiapoptotic actions. 44 Previous studies have indicated that p38 activation has a detrimental effect on cardiac function that leads to pathological hypertrophy rather than physiological compensation. 23 , 24 The enhanced activation of a MEK1-ERK1/2 signaling pathway and inhibition of p38 in the nitrite-treated hearts is also responsible for preventing the transition from compensated to decompensated heart failure.
We also investigated its effect in an ischemic-induced heart failure model. Previous studies indicate that nitrite is both a storage form of NO in tissues and also a source of NO in ischemic conditions. 45 Nitrite is cardioprotective during ischemia/ reperfusion injury via increasing nitrosothiol levels. 11, 46 Our results demonstrate that chronic nitrite therapy leads to significantly higher plasma nitrosothiol levels and higher myocardial nitrite levels.
Although the current study demonstrates that chronic nitrite therapy improves LV function after heart failure, there are some limitations that need to be noted. Because a mouse model was used, these data may not accurately predict human disease. Future studies need to be conducted in large animal models that are more clinically relevant. Another limitation is that mice used in this study are without any other comorbid conditions such as hypertension, hypercholesterolemia, and diabetes mellitus. We also started nitrite therapy at 24 hours after TAC that attenuated the progression of heart failure. Future studies need to evaluate nitrite therapy at a time when heart failure is fully developed. Figure 8 . Nitrite upregulates extracellular signal-regulated kinases (ERK1/2) and attenuates p38 phosphorylation. A, Representative immunoblots of (B) total ERK1/2 and (C) P-ERK1/2. Representative immunoblots of (D) total p38 and P-p38 in sham, TAC+vehicle, and TAC+nitrite treated mice after TAC at 1 and 6 weeks. E and F, Total p38 and P-p38. Results are expressed as mean±SEM. NS indicates nonsignificant.
In summary, we have demonstrated a cardioprotective action for sodium nitrite therapy on the severity of heart failure after TAC. Specifically, the current study provides evidence that chronic oral administration of sodium nitrite increases NO bioavailability and signaling after TAC-induced cardiac hypertrophy and failure. These results support the emerging concept that nitrite therapy may be a viable clinical option for increasing NO levels and may have a practical clinical use in the treatment of heart failure.
